> Detailanzeige

Lee, Bang‐Ning; Gao, Hui; Cohen, Evan N.; Badoux, Xavier; Wierda, William G.; Estrov, Zeev; Faderl, Stefan H.; Keating, Michael J.; Ferrajoli, Alessandra; Reuben, James M.

Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia
  • Beteiligte: Lee, Bang‐Ning; Gao, Hui; Cohen, Evan N.; Badoux, Xavier; Wierda, William G.; Estrov, Zeev; Faderl, Stefan H.; Keating, Michael J.; Ferrajoli, Alessandra; Reuben, James M.
  • Erschienen: Wiley, 2011
  • Erschienen in: Cancer, 117 (2011) 17, Seite 3999-4008
  • Sprache: Englisch
  • DOI: 10.1002/cncr.25983
  • ISSN: 0008-543X; 1097-0142
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractBACKGROUND:Lenalidomide, an immunomodulatory agent, has activity in lymphoproliferative disorders. The authors, therefore, evaluated its effects on T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia (CLL).METHODS:To study the immunomodulatory effects of lenalidomide in CLL, the authors recruited 24 patients with untreated CLL enrolled in a phase 2 clinical trial of lenalidomide and obtained peripheral blood specimens for immunologic studies consisting of enumeration of T cells and assessing their ability to synthesize cytokines after activation through T‐cell receptor (TCR).RESULTS:After 3 cycles of therapy, patients had a significant reduction in percentage (%) and absolute lymphocyte count (ALC) and an increase in percentage of T cells, percentage of activated CD8+ T cells producing IFN‐γ, and percentage of regulatory T (TR) cells when compared with their respective levels before treatment. After 15 cycles of treatment, responder patients had significant reduction in percentage of lymphocytes and ALC, percentage of activated CD4+ T cells producing IL‐2, IFN‐γ, or TNF‐α, and percentage of TR cells when compared with their perspective levels after 3 cycles of treatment. Furthermore, the numbers of activated CD4+ T cells producing IL‐2, IFN‐γ, or TNF‐α, activated CD8+ T cells producing IFN‐γ, and TR cells normalized to the range of healthy subjects.CONCLUSIONS:Treatment with lenalidomide resulted in the normalization of functional T‐cell subsets in responders, suggesting that lenalidomide may modulate cell‐mediated immunity in patients with CLL. Cancer 2011;. © 2011 American Cancer Society.
  • Zugangsstatus: Freier Zugang